Making stem cell transplants safer and more effective

For cancer patients, the use of hematopoietic stem cell transplants can be a game changer in terms of treatment and recovery. However, most people need to undergo a combination of chemotherapy and radiation before transplants become an option. A new article in Chemical & Engineering News, the weekly newsmagazine of the American Chemical Society, sheds light on progress toward making stem cell transplants safer and more effective.

Chemotherapy and radiation are used as a prelude to stem cell transplants in a process known as conditioning, writes Associate Editor Ryan Cross. This allows doctors to clear out diseased cells in the body and make room for healthy ones, but conditioning can be very harsh; it also kills healthy cells and can cause significant side effects, making recovery that much harder. Therefore, stem cell transplants are often under-used. Researchers and drug companies are now working to develop new targeted conditioning therapies with fewer side effects, which would allow more patients to safely undergo stem cell treatments.

The most promising approaches include using antibodies to target specific proteins on hematopoietic stem cells in a patient's body and kill those cells. The goal is to make room for new stem cells from the transplant and to avoid the collateral damage that chemotherapy and radiation cause to other cells. Experts believe this targeted conditioning will result in fewer side effects and could be applied to patients with cancer, genetic diseases and autoimmune disorders that want to receive stem cell transplants. Although there is reason for optimism on the basis of early findings, scientists caution that this new method may not fully solve the issues of side effects and immune rejection, and it may not be suitable for all types of cancers. In the meantime, work continues on advancing stem cell therapies, with the goals of better outcomes and fewer complications.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
PROSPECT-Lung trial aims to improve treatment for patients with resectable non-small cell lung cancer